Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder
NCT ID: NCT00322595
Last Updated: 2008-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
800 participants
INTERVENTIONAL
2006-05-31
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quetiapine fumarate
Paroxetine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A diagnosis of generalized anxiety disorder;
* Absence of current episode of major depression.
Exclusion Criteria
* Hypertension;
* A current diagnosis of cancer, unless in remission for at least 5 years
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seroquel Medical Science Director
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
City Bell, Buenos Aires, Argentina
Research Site
Godoy Cruz, Mendoza Province, Argentina
Research Site
Mendoza, Mendoza Province, Argentina
Research Site
Rosario, Santa Fe Province, Argentina
Research Site
Buenos Aires, , Argentina
Research Site
Córdoba, , Argentina
Research Site
La Plata, , Argentina
Research Site
Kardzhali, , Bulgaria
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Veliko Tarnovo, , Bulgaria
Research Site
Vratsa, , Bulgaria
Research Site
Kelowna, British Columbia, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Miramichi, New Brunswick, Canada
Research Site
Corner Brook, Newfoundland and Labrador, Canada
Research Site
Sydney, Nova Scotia, Canada
Research Site
Brantford, Ontario, Canada
Research Site
Chatham, Ontario, Canada
Research Site
Markham, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Orléans, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Gatineau, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Saskatoon, Saskatchewan, Canada
Research Site
Brno, , Czechia
Research Site
Litoměřice, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Pilsen, , Czechia
Research Site
Prague, , Czechia
Research Site
Prerova, , Czechia
Research Site
Prostojov, , Czechia
Research Site
Aarhus, , Denmark
Research Site
Copenhagen, , Denmark
Research Site
Frederiksberg, , Denmark
Research Site
Helsinki, , Finland
Research Site
Järvenpää, , Finland
Research Site
Salo, , Finland
Research Site
Turku, , Finland
Research Site
Angoulême, , France
Research Site
Arcachon, , France
Research Site
Cherbourg, , France
Research Site
Élancourt, , France
Research Site
La Valette-du-Var, , France
Research Site
Le Pecq, , France
Research Site
Nîmes, , France
Research Site
Rennes, , France
Research Site
Toulouse, , France
Research Site
Bad Saarow, , Germany
Research Site
Berlin, , Germany
Research Site
Bochum, , Germany
Research Site
Göttingen, , Germany
Research Site
Hamburg, , Germany
Research Site
München, , Germany
Research Site
Siegen, , Germany
Research Site
Distrito Federal, , Mexico
Research Site
Guadalajara, , Mexico
Research Site
México, , Mexico
Research Site
Brattvåg, , Norway
Research Site
Oslo, , Norway
Research Site
Paradis, , Norway
Research Site
Bucharest, , Romania
Research Site
Piteşti, , Romania
Research Site
Sibiu, , Romania
Research Site
Bojnice, , Slovakia
Research Site
Bratislava, , Slovakia
Research Site
Brezno, , Slovakia
Research Site
Košice, , Slovakia
Research Site
Liptovský Mikuláš, , Slovakia
Research Site
Zilina-Bytcica, , Slovakia
Research Site
Bloemfontein, , South Africa
Research Site
Cape Town, , South Africa
Research Site
Durban, , South Africa
Research Site
Pretoria, , South Africa
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Oviedo, , Spain
Research Site
Salamanca, , Spain
Research Site
Linköping, , Sweden
Research Site
Lund, , Sweden
Research Site
Malmo, , Sweden
Research Site
Sundsvall, , Sweden
Research Site
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Montgomery SA, Locklear JC, Svedsater H, Eriksson H. Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. 2014 Sep;29(5):252-62. doi: 10.1097/YIC.0000000000000026.
Stein DJ, Bandelow B, Merideth C, Olausson B, Szamosi J, Eriksson H. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies. Hum Psychopharmacol. 2011 Dec;26(8):614-28. doi: 10.1002/hup.1256. Epub 2011 Dec 6.
Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010 Apr;13(3):305-20. doi: 10.1017/S1461145709990423. Epub 2009 Aug 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2005-005054-46
Identifier Type: -
Identifier Source: secondary_id
Silver
Identifier Type: -
Identifier Source: secondary_id
D1448C00011
Identifier Type: -
Identifier Source: org_study_id